Table 1. Clinical pathological characteristics and molecular sub-type of stage 2 and stage 3 of breast cancer patients.
| Patient No. | Patient ID. | Stage | Histopathological Diagnosis | ER/PR/HER2 | TNBC | ANT |
|---|---|---|---|---|---|---|
| 1 | P2 | 2 | IDC | +/+/- | -- | + |
| 2 | P3 | 2 | IDC | +/-/+ | -- | + |
| 3 | P4 | 2 | IDC | +/+/- | -- | + |
| 4 | P5 | 2 | IDC | +/+/- | -- | + |
| 5 | P7 | 2 | IDC | +/+/+ | -- | + |
| 6 | P10 | 2 | IDC | +/+/- | -- | + |
| 7 | P20 | 2 | IDC | -/+/+ | -- | + |
| 8 | P21 | 2 | IDC | +/+/- | -- | + |
| 9 | P31 | 2 | IDC | +/+/- | -- | + |
| 10 | P32 | 2 | IDC | +/+/+ | -- | + |
| 11 | P40 | 2 | IDC | +/+/- | -- | + |
| 12 | P41 | 2 | IDC | +/+/+ | -- | + |
| 13 | P42 | 2 | IDC | +/+/- | -- | + |
| 14 | P64 | 2 | IDC | +/+/+ | -- | + |
| 15 | P65 | 2 | IDC | +/+/- | -- | + |
| 16 | P74 | 2 | IDC | +/+/- | -- | + |
| 17 | P78 | 2 | IDC | +/-/- | -- | + |
| 18 | P82 | 2 | IDC | +/+/+ | -- | + |
| 19 | P99 | 2 | IDC | +/+/- | -- | + |
| 20 | P113 | 2 | IDC | +/-/+ | -- | + |
| 21 | P114 | 3 | IDC | +/-/+ | -- | + |
| 22 | P115 | 3 | IDC | +/-/- | -- | + |
| 23 | P137 | 3 | IDC | +/-/- | -- | + |
| 24 | P138 | 3 | IDC | +/++ | -- | + |
| 25 | P139 | 3 | IDC | +/-/+ | -- | + |
| 26 | P147 | 3 | IDC | +/-/+ | -- | + |
| 27 | P148 | 3 | IDC | -/-/+ | -- | + |
| 28 | P150 | 3 | IDC | -/-/+ | -- | + |
| 29 | P156 | 3 | IDC | +/-/+ | -- | + |
| 30 | P157 | 3 | IDC | +/-/- | -- | + |
| 31 | P160 | 3 | IDC | +/-/- | -- | + |
| 32 | P161 | 3 | IDC | +/-/+ | -- | + |
| 33 | P165 | 3 | IDC | +/-/- | -- | + |
| 34 | P168 | 3 | IDC | +/+/+ | -- | + |
| 35 | P176 | 3 | IDC | +/+/+ | -- | + |
| 36 | P178 | 3 | IDC | +/+/+ | -- | + |
| 37 | P180 | 3 | IDC | +/+/+ | -- | + |
| 38 | P191 | 3 | IDC | +/+/+ | -- | + |
| 39 | P198 | 3 | IDC | +/-/+ | -- | + |
| 40 | P201 | 3 | IDC | +/-/- | -- | + |
IDC, Invasive ductal carcinoma; ER/PR/HER2, estrogen receptor/ progesterone receptor/ human epidermal growth factor receptor 2; TNBC, Triple-negative breast cancer; ANT, adjacent non-tumor breast tissue.